Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

709 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB. Lebwohl M, et al. Among authors: cross n. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00568-1. doi: 10.1016/j.jaad.2024.03.041. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38588819 Free article.
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A. Papp KA, et al. Among authors: cross n. J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10. doi: 10.1016/j.jaad.2018.03.037. Epub 2018 Mar 30. J Am Acad Dermatol. 2018. PMID: 29609013 Free article. Clinical Trial.
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, Wang M, Cioffi C, Griffiths CEM. Blauvelt A, et al. Among authors: cross n. J Am Acad Dermatol. 2020 Nov;83(5):1367-1374. doi: 10.1016/j.jaad.2020.05.105. Epub 2020 May 29. J Am Acad Dermatol. 2020. PMID: 32473974 Free article. Clinical Trial.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K. Warren RB, et al. Among authors: cross n. N Engl J Med. 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23. N Engl J Med. 2021. PMID: 33891379 Clinical Trial.
The effect of excessive gas to blood ratios in an ECMO oxygenator.
Shaw M, Cross N, Richardson R, Crook R, Thirulchelvam T, Issitt RW. Shaw M, et al. Among authors: cross n. Perfusion. 2024 May 23:2676591241256089. doi: 10.1177/02676591241256089. Online ahead of print. Perfusion. 2024. PMID: 38783478
Recommendations from the AML molecular MRD expert advisory board.
Scott S, Devonshire A, Dillon R, Thiede C, Cross NCP, White HE, Lo Cascio L, Mokretar K, Potter N, Hourigan CS, Radich J, Corner A, Laloux V, Halliday G, Dilks D, Morrison T, Gilmour K, Cartwright A, Whitby L. Scott S, et al. Among authors: cross ncp. Leukemia. 2024 May 23. doi: 10.1038/s41375-024-02275-x. Online ahead of print. Leukemia. 2024. PMID: 38783160 No abstract available.
709 results